Results section (Page 11, line 346): There was no difference in NR2F1 expression between responder and non-responder to neoadjuvant endocrine therapy (Supplementary Fig. 9).
Thus, we investigated the clinical relevance of the expression of NR2F1, a known dormancy biomarker.